Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule.
about
Cancer-treatment-induced neurotoxicity--focus on newer treatmentsHuman epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancerProof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platformOvercoming chemoresistance of small-cell lung cancer through stepwise HER2-targeted antibody-dependent cell-mediated cytotoxicity and VEGF-targeted antiangiogenesis.Lack of CD117 and rare bcl-2 expression in stomach cancer by immunohistochemistry. An immunohistochemical study with review of the literature.Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trialSevere thrombocytopenia after trastuzumab retreatment: a case report.The use and impact of cancer medicines in routine clinical care: methods and observations in a cohort of elderly AustraliansPersonalising pancreas cancer treatment: When tissue is the issue.Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101--Breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trHER2 status and breast cancer therapy: recent advances.A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer.Combination of osteopontin and activated leukocyte cell adhesion molecule as potent prognostic discriminators in HER2- and ER-negative breast cancer.Aromatase inhibitor strategies in metastatic breast cancer.Targeting HER2 in breast cancer: overview of long-term experienceThe epidermal growth factor receptor family in breast cancer.Role of lapatinib in the first-line treatment of patients with metastatic breast cancer.Efficacy of lapatinib monotherapy on occult breast cancer presenting with cutaneous metastases: A case reportEven low-level HER2 expression may be associated with worse outcome in node-positive breast cancer.Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancerDelayed Paclitaxel-trastuzumab-induced interstitial pneumonitis in breast cancer.Phase 1 combination study of eribulin mesylate with trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 positive breast cancer.Human epidermal growth factor receptor-2-positive breast cancer: Current management of early, advanced, and recurrent disease.Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity.Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II studyHER-2 assessment in formalin-fixed paraffin-embedded breast cancer tissue by well-based reverse phase protein arrayHer2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab.Infused therapy and survival in older patients diagnosed with metastatic breast cancer who received trastuzumab.Integrating molecular mechanisms and clinical evidence in the management of trastuzumab resistant or refractory HER-2⁺ metastatic breast cancer.Systematic Review of the Side Effects Associated With Anti-HER2-Targeted Therapies Used in the Treatment of Breast Cancer, on Behalf of the EORTC Quality of Life Group.Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer.Adjuvant therapy for HER2+ breast cancer: practice, perception, and toxicity.Effect of central nervous system metastases on treatment discontinuation and survival in older women receiving trastuzumab for metastatic breast cancer.Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy.Advances in first-line treatment for patients with HER-2+ metastatic breast cancer.Assessing HER2 amplification in breast cancer: findings from the Australian In Situ Hybridization Program.Docetaxel/trastuzumab combination therapy for the treatment of breast cancer.Trends in translational medicine and drug targeting and delivery: new insights on an old concept-targeted drug delivery with antibody-drug conjugates for cancers.Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group.Antibody therapy for early-stage breast cancer: trastuzumab adjuvant and neoadjuvant trials.
P2860
Q26782604-7CF982F9-6288-4C86-8966-45C18A16F23CQ27025863-70AB346C-F0FA-4CBF-9B2C-81833D43BE4AQ28596492-6F1C6F80-E7F0-4280-BB16-8B4B5E37B9CDQ30544833-C093FCC1-943F-4990-AE89-BF2A12C72061Q33246030-359BB0DD-5E77-4A28-89F0-896F6DE0A99FQ33279460-840DDCD6-F4EE-45B8-B196-FDA13A008219Q33410733-CFAE993E-3A53-4380-9C98-6E66442E0CB1Q33629327-189F9A85-11D6-41AA-BC13-AB7ED5AA0E1FQ33801384-674E349E-D5FE-4BFB-8622-0610715DB84CQ33973013-7FD5DC52-9392-4FEC-A905-B1A8E2A0781BQ34062418-97041CB3-F322-44ED-8585-4983533ED9E8Q34077853-9D19578A-E520-412E-B8CD-E8F05D4E329DQ34250074-3BE4615A-BE78-4788-867A-2509F143DFC4Q34272016-BCE27CAA-6CE3-47F0-AF42-F0845403489DQ34272044-C08E9F04-D443-4A38-AAF8-A13A016E2BB5Q34363400-523B9F64-41A8-4D4B-8828-0BA4CC56E06BQ34417920-E2C57DBE-CA4B-4597-A751-99018BC53C76Q34427231-92740F8B-EA22-488E-8AE7-860BB7DD3D0DQ34713799-D190D449-0681-4A2E-9899-15F0A60E1BBDQ34775370-310399B0-E922-4E16-8D37-93D3D14D4A24Q34832259-F6CD6D67-5331-4F2D-A7B4-C577BA31B33AQ34964991-7844D1ED-21E0-40B4-9973-3B43C71269C4Q35018233-18127F26-1E93-407F-9B4D-2CE5F46EDBC9Q35079683-0E1F7939-4BDC-4E75-A3E8-4E6A1D65B126Q35114038-2EEDD600-6249-4B34-B008-34176A5437FFQ35184966-F5E5DBB8-0859-4017-8CCA-C253BF963859Q35527141-7BC3B9CE-75EF-4AAD-96C8-AF4F04C4B0C9Q35540696-A457B101-1AFC-4822-BFDD-557ECF6403A8Q35599781-5F89A6A2-C8EE-4394-81EA-1B0485AA4422Q35871467-014019C5-B144-4085-B699-7ACA529276BFQ35880224-955EB28C-A7C8-4052-91FB-87FEAC276BE0Q35896366-6B19C0A6-4940-4703-986B-8C0A47CE1CAEQ35909243-7B71FFBE-D803-4903-A0C9-D68B8FCCAB28Q35927368-E2C277CA-207F-439C-8E84-670FDB92136DQ35989963-AFE406D7-D2A4-4B51-B11E-09DD21B3BFDBQ36107134-CAEEA621-6851-441E-BBA4-92B9A84FE71EQ36222001-602E064A-3FE9-4324-9EC1-B5C9BBBCC500Q36252918-75611E90-EF43-424D-B24F-4501B9FD2537Q36485216-7B4861E5-8183-4FBE-83D4-0EC955ADD171Q36569759-78C1418D-A1FD-49BE-82AC-E767920420BB
P2860
Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Phase II study of efficacy, sa ...... stered on a 3-weekly schedule.
@en
Phase II study of efficacy, sa ...... stered on a 3-weekly schedule.
@nl
type
label
Phase II study of efficacy, sa ...... stered on a 3-weekly schedule.
@en
Phase II study of efficacy, sa ...... stered on a 3-weekly schedule.
@nl
prefLabel
Phase II study of efficacy, sa ...... stered on a 3-weekly schedule.
@en
Phase II study of efficacy, sa ...... stered on a 3-weekly schedule.
@nl
P2093
P356
P1476
Phase II study of efficacy, sa ...... stered on a 3-weekly schedule.
@en
P2093
Claire Barton
José Baselga
Michael Clemens
Michael Green
Noel-Jaime Castañeda-Soto
Parviz Ghahramani
Serafin Morales
Vernon Harvey
Xavier Carbonell
P304
P356
10.1200/JCO.2005.01.014
P407
P577
2005-04-01T00:00:00Z